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OBJECTIVES To study the incidence of atorvastatin-induced
abnormal liver function in Chinese patients.
METHODS Literatures were searched in PubMed, EMBASE, CENTRAL,
SinoMed, CMCI, CNKI, VIP and Wanfang database (from their incep-
tion to Feb 8, 2015). Randomized controlled trial (RCT), Cohort Study,
case series and quasi-experiment studies were included, and generic
drugs were excluded. Data extraction and veriﬁcation were conducted
by two reviewers independently. Open Meta-Analyst software with
binary random effect model was applied to compute the incidence of
atorvastatin-induced abnormal liver function in different doses and
periods, and the results were described by rates and 95% conﬁdence
intervals (95% CI).
RESULTS According to our searching strategy and including criteria,
2386 literatures (2298 Chinese literatures and 88 English ones)
published between 2001 and 2015 were included, among which there
were 1984 RCT studies, 45 cohort studies, 258 case series studies and
99 quasi-experiment studies. 1140 literatures reported the adverse
drug reactions (ADRs) in the process of follow-up, but 1246 litera-
tures did not explicitly mentioned any ADRs. 182430 patients with
different diseases such as coronary heart disease, acute coronary
syndromes, unstable angina pectoris, hyperlipidemia, atherosclerosis
were analyzed. The maximum treatment time was 7 years. Based on
the studies reported ADRs (1140 literatures), the numbers of patients
in 10mg/d, 20mg/d, 40mg/d and 80mg/d groups were 29079, 54020,
9255 and 1216, respectively, and the corresponding incidence and
95%CI of atorvastatin-induced abnormal liver function were 1.1%
(0.9%w1.2%), 1.2% (1.1%w1.3%), 1.3% (1.1%w1.5%) and 2.7% (1.4%w
3.9%), respectively. There were no signiﬁcant differences among
different treatment periods in the same dose group. Based on all
2386 literatures, the numbers of patients were 52030, 106009, 18840
and 3352 in four groups, respectively, and corresponding incidence
of atorvastatin-induced abnormal liver function were 0.6% (0.5%w
0.7%), 0.03% (0.02%w0.05%), 0.6% (0.5%w0.7%) and 0.9% (0.6%w
1.2%) with the assume that those studies not mentioned ADRs were
the ones with no ADRs. When based on hepatic transaminases > 3
times the upper limit of normal in literatures reported ADRs, the
incidence and 95%CI of atorvastatin-induced hepatitis were 0.9%
(0.6%w1.1%), 0.9% (0.7%w1.1%), 1.0% (0.6%w1.3%) and 1.4%
(0.2%w2.5%) in 10mg/d, 20mg/d, 40mg/d and 80mg/d groups,
respectively. In addition, there were 6, 1, 10 and 17 literatures
described 5mg/d, 15mg/d, 30mg/d and 60mg/d, respectively, and
with few cases of abnormal liver function in each groups (2/566,
1/64, 11/592 and 14/977, respectively).
CONCLUSIONS The incidence of atorvastatin-induced abnormal liver
function in Chinese patients were very low.
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Effect of phosphocreatine on angiotensininIIinduced proliferation and
collagen synthesis in neonatal rat cardiac ﬁbroblasts
Zihan Wei, Ying Wang
the First Afﬁliated Hospital, Zhengzhou University
OBJECTIVES The aim of this study is to investigate the effect of
phosphocreatine (PCr) on angiotensinII(AngII)–induced cardiac
ﬁbroblasts in neonatal rats in vitro and to clarify its mechanismof
action.
METHODS The model of myocardial ﬁbrosis induced by AngIIwas
established, the effect of phosphocreatine on cultured cardiac ﬁbro-
blasts(CF) proliferation in the presence or absence of excessive
angiotensinII(AngII) was assessed by ﬂow cytometric assay, the area
of myocardial collagen was observed by VG staining and the expres-
sion of the phosphorylated extracellular signal-regulated kinase
(pERK1/2) was detected by immunohistochemistry in each group. The
cardiac ﬁbroblasts were randomly divided into four groups: ① the
control group② the AngII group (110-6mol/L)③ the phosphocreatine
treated group (10mmol/L) ④ the AngII þphosphocreatine treated
group (110-6mol/L þ10mmol/L).
RESULTS The model of myocardial ﬁbrosis was successfully estab-
lished. Compared to the control group, distribution of CFs in G0/G1
and G2/M phase in AngIIgroup was decreased (P<0.01) with
conversely, the increase of the proporation in S phase, the collagensynthesis and the expression of pERK1/2 protein of CFs(P<0.01).
However, no signiﬁcant difference was observed in cell cycle distri-
bution, collagen synthesis of CFs and the expression of pERK1/2
protein between the control and the phosphocreatine treated
group(P>0.05). Compared to the AngIIgroup, the percentage of CFs in
the G0/G1 phase and G2/M phase was increased with simultaneously,
the reduction of S phase and the collagen synthesis in AngIIþphos-
phocreatine treated group (P<0.01). Noteworthy, phospho-status of
ERK1/2 in the AngIIþphosphocreatine treated group demonstrated a
higher expression than that in the control group as well as lower than
in the AngIIgroup (P<0.01).
CONCLUSIONS Our study shows that phosphocreatine plays a crucial
role in the inhibition of myocardial ﬁbrosis induced by AngIIthrough
partially suppressing the CF proliferation and collagen synthesis,
which is possibly associated with the inhibition of excessively acti-
vated ERK1/2.GW26-e1296
A research on initial dosage of warfarin and target ratio
Guo Huijun, Xiuchun Yang, Jingchao Lu, Fan Liu
Second Hospital of Hebei Medical University
OBJECTIVES To further acknowledge the optimal initial dosage and
offer more reasonable evidence for the application of warfarin in
clinical work, the research is adopted by comparing the efﬁcacy
and safety of the two dosage regimens to the patients with atrial
ﬁbrillation (AF) or pulmonary embolism (PE) by using different
initial dosages of warfarin according to the warfarin 3mg and to the
BMI.
METHODS 81 patients using oral warfarin were randomly assigned to
two groups according to different kinds of dosage regimen. The con-
trol group included 42 cases started with 3 mg while research group
included 39 cases, started with the initial warfarin dosage by the guide
of body mass index (BMI) (BMI<25,3mg;25BMI<30,4.5mg;
BMI30,6mg). Follow up one month, to compare the time that INR
ﬁrst stabilized at target range(2.0w3.0), the ratio within stabilized
target range at different time, the time that INR stabilized at target
range, the times to exceed therapeutic INR (INR>3.0), maintenance
dose, and the incidence of bleeding or thrombosis episodes.
RESULTS There was no statistical signiﬁcance between the two
groups in baseline characteristics included age, sex, height, weight,
BMI, comorbid conditions, drug combination, Baseline INR, left atrial
thrombus and pulmonary embolism. Comparing the safety between
two groups: there were two cases bleeding slightly in control group
and one case in research group, Both groups had no thrombotic
events, There was no statistical signiﬁcance between the two groups
(P¼1.0). There were no statistical signiﬁcance between the two groups
in the incidence rate to exceed therapeutic INR in different time
(P>0.05).There was 7 cases in control group to exceed therapeutic INR
at day 15, and 13 cases in research group, There was no statistical
signiﬁcance between the two groups (P¼0.082, P>0.05). Comparing
the effectiveness between two groups: compared with control group,
the ratio to achieve therapeutic INR at day 3, day 5, day 7 were
signiﬁcantly higher in research group ( 38.9% vs. 11.9% at day 3, 51.3%
vs. 23.8% at day 5, 71.8% vs. 45.2% at day 7), There was statistical
signiﬁcance between the two groups (P<0.05). Compared with control
group, research group required a signiﬁcantly shorter time to achieve
therapeutic INR at the ﬁrst time (5 days vs. 7 days), There was sta-
tistical signiﬁcance between the two groups (P<0.05). There was no
statistical signiﬁcance between the two groups in the time that INR
stabilized therapeutic INR (12 days in research group vs. 15 days in
control group), but compared with control group, research group was
faster. There was statistical signiﬁcance between the two groups
(P<0.05) in maintenance dose.
CONCLUSIONS compared with 3 mg as initial dose, It is more rapid
and more effective to achieve therapeutic INR according to body mass
index (BMI) guiding the initial warfarin dosage, and bleeding event
did not add at the same time.GW26-e4473
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